Home The Action Objectives



Primary Objective
The main objective of the Action is to boost the quality, competitiveness and impact of European biomedical research in the field of gasotransmitter molecules (NO, CO and H2S) and to translate the progress made into potential therapies. The network will pool, categorize and share specific knowledge, skills, expertise and reagents among the ENOG participants; the formation of the Action will also increase the targeted interactions between a multi-disciplinary group of researchers with expertise that ranges from computational and synthetic chemistry to pharmacology, drug design and development.

Secondary Objectives
The following secondary objectives are an integral and important part of ENOG, and include:

  1. Rapid dissemination of specialised knowledge, experience and skills contributed by each participating group, both to other ENOG members as well as to the international community at large
  2. Application of knowledge to the development of novel bioactive compounds that have therapeutic potential. We believe that the participation of small medium enterprises (SME) with expertise in developing NO-modifying and CO-releasing molecules will aid greatly in this direction.
  3. Training of young researchers, to ensure continuation and expansion of research in the field

Memorandum of Understanding

COST Vademecum (Part B) – Grant System



POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.